SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation - PubMed (original) (raw)
SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation
J M Desterro et al. Mol Cell. 1998 Aug.
Free article
Abstract
Activation of NF-kappaB is achieved by ubiquitination and proteasome-mediated degradation of IkappaBalpha. We have detected modified IkappaBalpha, conjugated to the small ubiquitin-like protein SUMO-1, which is resistant to signal-induced degradation. In the presence of an E1 SUMO-1-activating enzyme, Ubch9 conjugated SUMO-1 to IkappaBalpha primarily on K21, which is also utilized for ubiquitin modification. Thus, SUMO-1-modified IkappaBalpha cannot be ubiquitinated and is resistant to proteasome-mediated degradation. As a result, overexpression of SUMO-1 inhibits signal-induced activation of NF-kappaB-dependent transcription. Unlike ubiquitin modification, which requires phosphorylation of S32 and S36, SUMO-1 modification of IkappaBalpha is inhibited by phosphorylation. Thus, while ubiquitination targets proteins for rapid degradation, SUMO-1 modification acts antagonistically to generate proteins resistant to degradation.
Similar articles
- Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.
Hay RT, Vuillard L, Desterro JM, Rodriguez MS. Hay RT, et al. Philos Trans R Soc Lond B Biol Sci. 1999 Sep 29;354(1389):1601-9. doi: 10.1098/rstb.1999.0504. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10582246 Free PMC article. Review. - Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo.
Roff M, Thompson J, Rodriguez MS, Jacque JM, Baleux F, Arenzana-Seisdedos F, Hay RT. Roff M, et al. J Biol Chem. 1996 Mar 29;271(13):7844-50. doi: 10.1074/jbc.271.13.7844. J Biol Chem. 1996. PMID: 8631829 - Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway.
Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T. Tanaka K, et al. Biochimie. 2001 Mar-Apr;83(3-4):351-6. doi: 10.1016/s0300-9084(01)01237-8. Biochimie. 2001. PMID: 11295496 Review.
Cited by
- Posttranslational Modifications of α-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.
Hassanzadeh K, Liu J, Maddila S, Mouradian MM. Hassanzadeh K, et al. Pharmacol Rev. 2024 Oct 16;76(6):1254-1290. doi: 10.1124/pharmrev.123.001111. Pharmacol Rev. 2024. PMID: 39164116 Free PMC article. Review. - Crosstalk between SUMOylation and other post-translational modifications in breast cancer.
Wei B, Yang F, Yu L, Qiu C. Wei B, et al. Cell Mol Biol Lett. 2024 Aug 10;29(1):107. doi: 10.1186/s11658-024-00624-3. Cell Mol Biol Lett. 2024. PMID: 39127633 Free PMC article. Review. - Targeted inhibition of SUMOylation: treatment of tumors.
Zhao H, Zhao P, Huang C. Zhao H, et al. Hum Cell. 2024 Sep;37(5):1347-1354. doi: 10.1007/s13577-024-01092-9. Epub 2024 Jun 10. Hum Cell. 2024. PMID: 38856883 Review. - A UL26-PIAS1 complex antagonizes anti-viral gene expression during Human Cytomegalovirus infection.
Ciesla J, Huang KL, Wagner EJ, Munger J. Ciesla J, et al. PLoS Pathog. 2024 May 20;20(5):e1012058. doi: 10.1371/journal.ppat.1012058. eCollection 2024 May. PLoS Pathog. 2024. PMID: 38768227 Free PMC article. - SUMOylation regulation of ribosome biogenesis: Emerging roles for USP36.
Yang Y, Li Y, Sears RC, Sun XX, Dai MS. Yang Y, et al. Front RNA Res. 2024;2:1389104. doi: 10.3389/frnar.2024.1389104. Epub 2024 Apr 3. Front RNA Res. 2024. PMID: 38764604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous